Abstract:Background: Cerebral cavernous malformations (CCMs) are vascular disorders with a diverse natural history causing stroke and epilepsy. This multicenter cohort study aimed to unravel the correlation between genotype and clinical presentation in CCMs. Methods: We conducted a multicenter cohort study across three reference centers in China. In this study, we employed whole-exome sequencing, droplet digital PCR, and targeted panel sequencing to analyze 290 surgical specimens of CCMs. We also conducted an observational study of patients managed conservatively prior to surgical resection of CCMs to elucidate their natural history. Findings: Between January 2013 and May 2023, 201 out of 290 surgically resected CCMs had mutations in MAP3K3, PIK3CA, or CCM germline mutations, and were subsequently included in further analysis. Patients with solitary PIK3CA mutations exhibited a higher likelihood of hemorrhage (P < .001), while those with MAP3K3 mutations were more prone to epilepsy onset (P < .001). The mutation spectrum correlated with various clinical parameters, influencing hemorrhage risk (P < .001), lesion diameter (P = .020), onset of non-hemorrhage epilepsy (P < .001), Zabramski classifications (P < .001), DVA (P < .001) and edema in the MRI appearance (P < .001). Over the study period, patients with PIK3CA mutations showed significantly higher 1-, 2-, and 5-year cumulative risks of hemorrhage (34.8%, 51.7%, and 62.7%, respectively) higher cumulative risks of hemorrhage compared to MAP3K3 mutations (P < .017) and double mutations (P < .001). Adjusted analyses confirmed the increased risk of subsequent hemorrhage in patients with PIK3CA mutations (adjusted HR = 8.816, 95% CI: 1.478-9.855, P = .045). Independent risk factors for epilepsy included age of onset (adjusted OR = 0.956, 95% CI: 0.928-0.983, P = .002), lesion diameter (adjusted OR= 0.545, 95% CI: 0.325-0.914, P = .021), and lesion locations (adjusted OR = 0.545, 95% CI: 0.325-0.914, P < .001). Notably, patients with germline mutations experienced earlier symptom onset (P = .003) and larger lesions (P = .019) compared to those with somatic mutations. Interpretation: This study's findings highlight a significant correlation between CCM genotype and clinical phenotypes, particularly regarding hemorrhage risk and seizures. The results offer insights into predicting the clinical course of CCM patients with different phenotypes, potentially leading to personalized treatment adjustments.Funding: National Natural Science Foundation of China (No. 82220108010, 81971104, 82201440, 82122020, 82101369, 82102009 and 82330038). Beijing Municipal Commission of Education (BPHR20220113).Declaration of Interest: Tao Hong, Hongqi Zhang, Jian Ren report grants from National Natural Science Foundation of China. Tao Hong reports grants from Beijing Municipal Commission of Education. Hongqi Zhang, and Tao Hong declare no competing interests.Ethical Approval: This study was conducted in compliance with the approval of the local ethics committee and involved a prospectively maintained database. Furthermore, all patients provided informed consent, or consent was obtained from their legal guardian in cases involving participants with cognitive impairment or those aged younger than 18 years.

Plasma biomarkers in patients with familial cavernous malformation and their first-degree relatives

Circulating biomarkers in familial cerebral cavernous malformation

Prevalence, genetic and clinical characteristics in first-degree relatives of patients with familial cerebral cavernous malformations in China

Proteomics on human cerebral cavernous malformations reveals novel biomarkers in neurovascular dysfunction for the disease pathology

Multiple cerebral cavernous malformations: Clinical course of confirmed, assumed and non‐familial disease

Genetic variants in FCGR2A, PTPN2, VDR as predictive signatures of aggressive phenotypes in cerebral cavernous malformation

Abstract TMP1: Multi-omic Biomarker Development In A Mendelian Neurovascular Disease, Cavernous Angioma

Novel KRIT1/CCM1 and MGC4607/CCM2 Gene Variants in Chinese Families with Cerebral Cavernous Malformations

Genetic Markers and Predictive Factors Influencing the Aggressive Behavior of Cerebral Cavernous Malformation

Identification of a Novel CCM1 Frameshift Mutation in a Chinese Han Family With Multiple Cerebral Cavernous Malformations

Abstract WP17: Plasma Proteins In Correlation With Lesional Iron Content And Permeability Imaging In Clinical Trial Of Cavernous Angioma With Symptomatic Hemorrhage

Correlation of Genotype and Clinical Phenotype in Cerebral Cavernous Malformations: A Multicenter Cohort Study

Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Clinical, Pathological, Magnetic Resonance Imaging Features of a Chinese Family with Cerebral Cavernous Malformation Induced by a Novel CCM1 Gene Mutation (P07.232)

Probing the diagnostic values of plasma cf-nDNA and cf-mtDNA for Parkinson's disease and multiple system atrophy

Transcriptomic signatures of individual cell types in cerebral cavernous malformation

Innovative Quantitative Analysis for Disease Progression Assessment in Familial Cerebral Cavernous Malformations

The Value of Plasma Fibrillin-1 Level in Patients with Spontaneous Coronary Artery Dissection.

Serum Placental Growth Factor as a Marker of Cerebrovascular Disease Burden in Alzheimer's Disease

A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)